CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

Goldman Sachs Adjusts Price Target on Biogen to $290 From $271, Maintains Buy Rating

Positive
AI Analysis

Summary

Goldman Sachs raised its price target on Biogen to $290 from $271 while maintaining a Buy rating.

Importance:2/10
Sentiment:
0.30
analyst_ratingprice_targetequity_research
Related Companies

Read the original article

Published by yahoo_finance on July 30, 2026 1:57 PM

Read Original